Crinetics Pharmaceuticals, Inc.
$84.95$0.00 (0.0%)
Last close · Data as of Sep 2, 2026
- Market cap
- $3.7B
- P/E
- -7.8x
- EV / EBITDA
- -7.0x
- Revenue
- $7.7M
- Net margin
- -6046.2%
- ROCE
- -49.6%
Price chart
Technical chartScreen technicals →Hidden because the last close is more than three trading days older than the latest prices of its class.
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 2 Sep 2026 close.
- 1M
- Stale
- 3M
- Stale
- 6M
- Stale
- 1Y
- Stale
- 5Y
- Stale
- Hidden because the last close is more than three trading days older than the latest prices of its class.
52-week range
Day change $0.00 (0.0%) from $85 to $85 · Last close Sep 2, 2026
Best weekday to invest, historically
The same weekly amount in CRNX, bought on each weekday since 2021.
News & filings
What Crinetics Pharmaceuticals filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 465 million US dollars in fiscal 2025.
Strengths (1)
- Revenue more than doubled in fiscal 2025.
- Prices are as of 2 Sep 2026; price-based points are paused until newer prices arrive.
Prices to the 2 Sep 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Read moreShow less
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; and SST3 Agonist program for the treatment of polycystic kidney disease, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Shares outstanding
- 95.6M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $3.7B
- P/E
- -7.8x
- P/B
- 3.7x
- EV / EBITDA
- -7.0x
- EV / Sales
- 467.6x
- P/S
- 474.5x
- 52-week high
- $84.95
- 52-week low
- $32.61
Profitability
- Operating margin
- -6714.8%
- Net margin
- -6046.2%
- EBITDA margin
- -6664.2%
- ROE
- -46.9%
- ROCE
- -49.6%
- ROIC
- -43.5%
- ROA
- -41.3%
- Asset turnover
- 0.01
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $7.7M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 640.7%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 17.6%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 55.9%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- -$383.7M
Solvency
- Current ratio
- 12.32
- Debt / Equity
- 0.05
- Debt / Assets
- 0.04
- CFO / Net profit
- 0.81
- Cash / Market cap
- 2.8%
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Revenue | $7.7M |
| Cost of revenue | $1.1M |
| Gross profit | $6.6M |
| Operating expenses | $523.4M |
| Research and development | $332.1M |
| Selling, general and administrative | $191.3M |
| Operating income | -$516.8M |
| Interest and other | $51.6M |
| Pretax income | -$465.1M |
| Tax and other | $180.0k |
| Net income | -$465.3M |
Revenue and net profit
Revenue grew 640.7% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $4.7M | -$163.9M |
| FY2023 | $4.0M | -$214.5M |
| FY2024 | $1.0M | -$298.4M |
| FY2025 | $7.7M | -$465.3M |
Cash flows
FY2025: -$377.9M from operations, -$383.7M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$115.2M | -$116.9M |
| FY2023 | -$168.6M | -$173.3M |
| FY2024 | -$230.2M | -$234.0M |
| FY2025 | -$377.9M | -$383.7M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $7.7M+640.7%1Y
- EBITDA
- -$512.9M
- Net profit
- -$465.3M
- Cash from operations
- -$377.9M
- Free cash flow
- -$383.7M
- Revenue CAGR, 3Y
- 17.6%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $7.7M | -$512.9M | -$465.3M | -$383.7M | -46.9% | +640.7% | +55.9% |
Monthly returns
Month-by-month returns of CRNX across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $1.1B |
| Current assets | $1.0B |
| Non-current assets | $77.9M |
| Liabilities | $134.2M |
| Current liabilities | $85.1M |
| Non-current liabilities | $49.1M |
| Equity | $992.1M |
| Retained earnings | -$1.4B |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; CRNX highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Not shown (no positive earnings and no EV / Sales): Erasca, Inc., Edgewise Therapeutics, Inc., Oruka Therapeutics, Inc., Denali Therapeutics Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Crinetics Pharmaceuticals, Inc.CRNXthis company | $3.7B | -7.8x | 3.7x | -46.9% | -7.0x |
| Erasca, Inc.ERAS | $4.1B | -33.1x | 12.7x | -38.3% | -32.0x |
| LivaNova PLCLIVN | $4.0B | -16.7x | 3.4x | -20.2% | -34.4x |
| Edgewise Therapeutics, Inc.EWTX | $4.0B | -23.9x | 7.7x | -32.1% | -20.9x |
| Oruka Therapeutics, Inc.ORKA | $3.8B | — | 9.9x | -22.5% | — |
| iRhythm Holdings, Inc.IRTC | $3.5B | -79.2x | 23.1x | -29.2% | -1014.6x |
| Beam Therapeutics Inc.BEAM | $3.4B | -42.2x | 2.7x | -6.5% | -9.0x |
| Tango Therapeutics, Inc.TNGX | $3.2B | -31.5x | 9.3x | -29.3% | -28.7x |
| Denali Therapeutics Inc.DNLI | $3.2B | -6.2x | 3.2x | -50.6% | -5.6x |
| Peer median | — | -31.5x | 8.5x | -29.3% | -28.7x |
Year-to-date ROI
CRNX since 1 January, against earlier years.
Historical volatility
CRNX's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | -3541.8% |
| FY2023 | -5551.4% |
| FY2024 | -32581.7% |
| FY2025 | -6711.3% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $7.7M |
| Cost of revenueCost Of Revenue | $1.1M |
| Gross profitGross Profit | $6.6M |
| Operating expensesOperating Expense | $523.4M |
| Research and developmentResearch And Development | $332.1M |
| Selling, general and administrativeSelling General And Administration | $191.3M |
| Total expensesTotal Expenses | $524.5M |
| Operating incomeOperating Income | -$516.8M |
| Interest and other | |
| Pretax incomePretax Income | -$465.1M |
| TaxTax Provision | $180.0k |
| Net incomeNet Income | -$465.3M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $1.1B |
| Current assetsCurrent Assets | $1.0B |
| Non-current assetsTotal Non Current Assets | $77.9M |
| LiabilitiesTotal Liabilities Net Minority Interest | $134.2M |
| Current liabilitiesCurrent Liabilities | $85.1M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $49.1M |
| EquityTotal Equity Gross Minority Interest | $992.1M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | -$377.9M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | -$377.9M |
| Net income, continuing operationsNet Income From Continuing Operations | -$465.3M |
| Depreciation and amortisationDepreciation And Amortization | $3.9M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $3.9M |
| Amortization of securitiesAmortization Of Securities | -$15.4M |
| Stock-based compensationStock Based Compensation | $91.0M |
| Operating gains and lossesOperating Gains Losses | $50.0k |
| Gain loss on investment securitiesGain Loss On Investment Securities | — |
| Gain loss on sale of PP&EGain Loss On Sale Of PPE | $50.0k |
| Earnings losses from equity investmentsEarnings Losses From Equity Investments | $0.00 |
| Change in working capitalChange In Working Capital | $4.8M |
| Other non-cash itemsOther Non Cash Items | $3.0M |
| Investing cash flowInvesting Cash Flow | $173.9M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | $173.9M |
| Capital expenditureCapital Expenditure | -$5.8M |
| Purchase of PP&EPurchase Of PPE | -$5.8M |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$5.8M |
| Purchase of investmentsPurchase Of Investment | -$1.0B |
| Sale of investmentsSale Of Investment | $1.2B |
| Net investment purchases and salesNet Investment Purchase And Sale | $179.7M |
| Financing cash flowFinancing Cash Flow | $40.6M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $40.6M |
| Shares issuedIssuance Of Capital Stock | $0.00 |
| Common stock issuedCommon Stock Issuance | $0.00 |
| Net common stock issuedNet Common Stock Issuance | $0.00 |
| Common stock repurchasedCommon Stock Payments | $0.00 |
| Share buybacksRepurchase Of Capital Stock | $0.00 |
| Stock options exercisedProceeds From Stock Option Exercised | $40.6M |
| Change in cashChanges In Cash | -$163.4M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | -11.0% |
| Cash at the start of the yearBeginning Cash Position | $265.9M |
| Cash at the end of the yearEnd Cash Position | $102.3M |
| Free cash flowFree Cash Flow | -$383.7M |
Learn while you research
Academy chapters picked for Crinetics Pharmaceuticals, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Growth Investing641% revenue growth is in the top tier, learn how to value growth.7 min read
- 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read